Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting Analysis
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease globally. The impact of statins on liver fibrosis severity in MASLD individuals remains uncertain, despite their known cardiovascular benefits. Methods: A cross-secti...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Livers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-4389/4/4/46 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846103880070332416 |
|---|---|
| author | Natchaya Polpichai Sakditad Saowapa Aunchalee Jaroenlapnopparat Leandro Sierra Pojsakorn Danpanichkul Panisara Fangsaard Phuuwadith Wattanachayakul Apichat Kaewdech |
| author_facet | Natchaya Polpichai Sakditad Saowapa Aunchalee Jaroenlapnopparat Leandro Sierra Pojsakorn Danpanichkul Panisara Fangsaard Phuuwadith Wattanachayakul Apichat Kaewdech |
| author_sort | Natchaya Polpichai |
| collection | DOAJ |
| description | Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease globally. The impact of statins on liver fibrosis severity in MASLD individuals remains uncertain, despite their known cardiovascular benefits. Methods: A cross-sectional study was performed utilizing the National Health and Nutrition Examination Survey (NHANES) database from 2017 to 2018. MASLD was defined by hepatic steatosis (controlled attenuation parameter [CAP] score ≥ 288 dB/m) without other etiologies. Using inverse probability treatment weighting to minimize confounding, we examined the association between statin use and MASLD outcomes, including at-risk steatohepatitis (FibroScan-aspartate aminotransferase [AST] [FAST] score ≥ 0.67), significant and advanced fibrosis (liver stiffness measurement [LSM] ≥ 8.8 kilopascals [kPa] and ≥ 11.7 kPa), and advanced fibrosis (AGILE 3+ score ≥ 0.68). Results: Of 1283 MASLD patients, 376 were prescribed statins within the past 30 days. After adjustment for confounders, statin use was significantly associated with reduced risks of at-risk steatohepatitis, significant fibrosis, and high AGILE 3+ scores, with odds ratios (ORs) of 0.29 (95% CI: 0.01 to 0.87), 0.54 (95% CI: 0.31 to 0.95), and 0.41 (95% CI: 0.22 to 0.75), respectively. However, a subgroup analysis showed this effect persisted only with lipophilic statins. Conclusions: Statin use was associated with reduced steatohepatitis and fibrosis in patients with MASLD, supported by robust causal inference and vibration-controlled transient elastography-derived scores. |
| format | Article |
| id | doaj-art-b39a884693b84a1a808dc41f3efebded |
| institution | Kabale University |
| issn | 2673-4389 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Livers |
| spelling | doaj-art-b39a884693b84a1a808dc41f3efebded2024-12-27T14:36:31ZengMDPI AGLivers2673-43892024-12-014467768710.3390/livers4040046Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting AnalysisNatchaya Polpichai0Sakditad Saowapa1Aunchalee Jaroenlapnopparat2Leandro Sierra3Pojsakorn Danpanichkul4Panisara Fangsaard5Phuuwadith Wattanachayakul6Apichat Kaewdech7Department of Medicine, Weiss Memorial Hospital, Chicago, IL 60640, USADepartment of Medicine, Texas Tech University Health Science Center, Lubbock, TX 79430, USADigestive Health Institute, Orlando Health, Orlando, FL 32806, USADepartment of Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USADepartment of Medicine, Texas Tech University Health Science Center, Lubbock, TX 79430, USADepartment of Internal Medicine, Bassett Medical Center, Cooperstown, NY 13326, USADepartment of Internal Medicine, Einstein Medical Center, Philadelphia, PA 19141, USAGastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, ThailandBackground/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease globally. The impact of statins on liver fibrosis severity in MASLD individuals remains uncertain, despite their known cardiovascular benefits. Methods: A cross-sectional study was performed utilizing the National Health and Nutrition Examination Survey (NHANES) database from 2017 to 2018. MASLD was defined by hepatic steatosis (controlled attenuation parameter [CAP] score ≥ 288 dB/m) without other etiologies. Using inverse probability treatment weighting to minimize confounding, we examined the association between statin use and MASLD outcomes, including at-risk steatohepatitis (FibroScan-aspartate aminotransferase [AST] [FAST] score ≥ 0.67), significant and advanced fibrosis (liver stiffness measurement [LSM] ≥ 8.8 kilopascals [kPa] and ≥ 11.7 kPa), and advanced fibrosis (AGILE 3+ score ≥ 0.68). Results: Of 1283 MASLD patients, 376 were prescribed statins within the past 30 days. After adjustment for confounders, statin use was significantly associated with reduced risks of at-risk steatohepatitis, significant fibrosis, and high AGILE 3+ scores, with odds ratios (ORs) of 0.29 (95% CI: 0.01 to 0.87), 0.54 (95% CI: 0.31 to 0.95), and 0.41 (95% CI: 0.22 to 0.75), respectively. However, a subgroup analysis showed this effect persisted only with lipophilic statins. Conclusions: Statin use was associated with reduced steatohepatitis and fibrosis in patients with MASLD, supported by robust causal inference and vibration-controlled transient elastography-derived scores.https://www.mdpi.com/2673-4389/4/4/46StatinsMASLDNAFLDMASHNASHliver fibrosis |
| spellingShingle | Natchaya Polpichai Sakditad Saowapa Aunchalee Jaroenlapnopparat Leandro Sierra Pojsakorn Danpanichkul Panisara Fangsaard Phuuwadith Wattanachayakul Apichat Kaewdech Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting Analysis Livers Statins MASLD NAFLD MASH NASH liver fibrosis |
| title | Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting Analysis |
| title_full | Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting Analysis |
| title_fullStr | Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting Analysis |
| title_full_unstemmed | Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting Analysis |
| title_short | Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting Analysis |
| title_sort | statin use in metabolic dysfunction associated steatotic liver disease and effects on vibration controlled transient elastography derived scores a population based inverse probability treatment weighting analysis |
| topic | Statins MASLD NAFLD MASH NASH liver fibrosis |
| url | https://www.mdpi.com/2673-4389/4/4/46 |
| work_keys_str_mv | AT natchayapolpichai statinuseinmetabolicdysfunctionassociatedsteatoticliverdiseaseandeffectsonvibrationcontrolledtransientelastographyderivedscoresapopulationbasedinverseprobabilitytreatmentweightinganalysis AT sakditadsaowapa statinuseinmetabolicdysfunctionassociatedsteatoticliverdiseaseandeffectsonvibrationcontrolledtransientelastographyderivedscoresapopulationbasedinverseprobabilitytreatmentweightinganalysis AT aunchaleejaroenlapnopparat statinuseinmetabolicdysfunctionassociatedsteatoticliverdiseaseandeffectsonvibrationcontrolledtransientelastographyderivedscoresapopulationbasedinverseprobabilitytreatmentweightinganalysis AT leandrosierra statinuseinmetabolicdysfunctionassociatedsteatoticliverdiseaseandeffectsonvibrationcontrolledtransientelastographyderivedscoresapopulationbasedinverseprobabilitytreatmentweightinganalysis AT pojsakorndanpanichkul statinuseinmetabolicdysfunctionassociatedsteatoticliverdiseaseandeffectsonvibrationcontrolledtransientelastographyderivedscoresapopulationbasedinverseprobabilitytreatmentweightinganalysis AT panisarafangsaard statinuseinmetabolicdysfunctionassociatedsteatoticliverdiseaseandeffectsonvibrationcontrolledtransientelastographyderivedscoresapopulationbasedinverseprobabilitytreatmentweightinganalysis AT phuuwadithwattanachayakul statinuseinmetabolicdysfunctionassociatedsteatoticliverdiseaseandeffectsonvibrationcontrolledtransientelastographyderivedscoresapopulationbasedinverseprobabilitytreatmentweightinganalysis AT apichatkaewdech statinuseinmetabolicdysfunctionassociatedsteatoticliverdiseaseandeffectsonvibrationcontrolledtransientelastographyderivedscoresapopulationbasedinverseprobabilitytreatmentweightinganalysis |